PGEN Return on Tangible Equity | PRECIGEN, INC.

PRECIGEN, INC. (PGEN) Return on Tangible Equity

2026-06-30: Return Tang Equity -626.76%.
2026-03-31: Return Tang Equity -11225.59%.
2025-12-31: Return Tang Equity -10037.73%.
2025-09-30: Return Tang Equity -1112.96%.

Complete source-backed return tang equity history.

Available history: 2011-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical Return Tang Equity

Date	Return Tang Equity
2026-06-30	-626.76%
2026-03-31	-11225.59%
2025-12-31	-10037.73%
2025-09-30	-1112.96%
2025-06-30	220.49%
2025-03-31	416.02%
2024-12-31	-846.14%
2024-09-30	1362.53%
2024-06-30	603.06%
2024-03-31	-325.60%
2023-12-31	-187.37%
2023-09-30	-120.84%
2023-06-30	25.58%
2023-03-31	24.04%
2022-12-31	63.09%
2022-09-30	40.15%
2022-06-30	337.77%
2022-03-31	301.56%
2021-12-31	-526.57%
2021-09-30	-540.53%
2021-06-30	-241.30%
2021-03-31	-222.23%
2020-12-31	324.28%
2020-09-30	491.04%
2020-06-30	464.68%
2020-03-31	708.64%
2019-12-31	635.07%
2019-09-30	5813.59%
2019-06-30	-1232.53%
2019-03-31	-714.59%
2018-12-31	-282.55%
2018-09-30	-115.86%
2018-06-30	-99.58%
2018-03-31	-79.16%
2017-12-31	-56.53%
2017-09-30	-106.35%
2017-06-30	-84.62%
2017-03-31	-104.03%
2016-12-31	-105.16%
2016-09-30	-86.68%
2016-06-30	-86.32%
2016-03-31	-71.87%
2015-12-31	-30.03%
2015-09-30	-11.16%
2015-06-30	-24.51%
2015-03-31	-14.45%
2014-12-31	-37.58%
2014-09-30	-58.97%
2014-06-30	-15.23%
2014-03-31	0.43%
2013-12-31	-12.54%
2013-09-30	-17.98%

Annual Return Tang Equity

Date	Return Tang Equity
2025-12-31	-10037.73%
2024-12-31	-846.14%
2023-12-31	-187.37%
2022-12-31	63.09%
2021-12-31	-526.57%
2020-12-31	324.28%
2019-12-31	635.07%
2018-12-31	-282.55%
2017-12-31	-56.53%
2016-12-31	-105.16%
2015-12-31	-30.03%
2014-12-31	-37.58%
2013-12-31	-12.54%
2012-12-31	23.32%
2011-12-31	38.54%

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)		$2.719B	-15.37
MBX Biosciences, Inc. (MBX)	United States	$2.664B	-25.36
Disc Medicine, Inc. (IRON)	United States	$2.553B	-11.40
Immunome Inc. (IMNM)	United States	$2.538B	-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)	United States	$2.517B	-24.63
Nurix Therapeutics, Inc. (NRIX)	United States	$2.457B	-5.39
Dyne Therapeutics, Inc. (DYN)	United States	$3.084B	-7.09
SELLAS Life Sciences Group, Inc. (SLS)	United States	$2.420B	-91.87
uniQure N.V. (QURE)		$2.416B	-4.93
Vera Therapeutics, Inc. (VERA)	United States	$2.402B	-7.67